Q2 ‘22 was weakest quarter for biotech IPOs in more than 5 years

It’s unsurprising that the second quarter of 2022 was a low point for biotechs going public. Until the middle of June, indexes for the industry, namely the XBI biotech fund, were spiraling, a clear warning sign for companies considering launching an IPO.